Clinical Trials

Showing trials with last updates posted in 2026.

NCT03911388 | RECRUITING | PHASE1
24 participants

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-01
Start Date:
2019-09-12
Completion:
2026-09-01
Conditions
  • Neoplasms, Brain
  • Glioblastoma Multiforme
  • Glioblastoma of Cerebellum
  • Neoplasms
  • Astrocytoma
  • Astrocytoma, Cerebellar
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Cerebellar PNET, Childhood
  • Cerebellar Neoplasms
  • Cerebellar Neoplasms, Primary
  • Cerebellar Neoplasm, Malignant
  • Cerebellar Neoplasm Malignant Primary
  • Neoplasm Metastases
  • Neoplasm Malignant
  • Neoplasms, Neuroepithelial
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms by Histologic Type
  • Neoplasms, Glandular and Epithelial
  • Neoplasms, Nerve Tissue
  • Central Nervous System Neoplasms, Primary
  • Central Nervous System Neoplasms, Malignant
  • Nervous System Neoplasms
  • Neoplasms by Site
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Medulloblastoma Recurrent
  • HSV
  • Virus
  • Pediatric Brain Tumor
  • Nervous System Cancer
  • Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
  • BIOLOGICAL
No Results Yet
NCT03801434 | ACTIVE_NOT_RECRUITING | PHASE2
8 participants

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-01
Start Date:
2019-11-15
Completion:
2029-02-28
Conditions
  • BCR-JAK2 Fusion Protein Expression
  • Blasts 20 Percent or Less of Peripheral Blood White Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Peripheral Blood White Cells
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified
  • Eosinophilia
  • Hepatomegaly
  • Hypereosinophilic Syndrome
  • JAK2 Gene Mutation
  • Splenomegaly
  • TEL-JAK2 Fusion Protein Expression
Interventions
  • DRUG
No Results Yet
NCT03739814 | RECRUITING | PHASE2
84 participants

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-01
Start Date:
2019-05-08
Completion:
2027-02-01
Conditions
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Recurrent B Acute Lymphoblastic Leukemia
  • Refractory B Acute Lymphoblastic Leukemia
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT03604991 | SUSPENDED | PHASE2/PHASE3
278 participants

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-01
Start Date:
2019-05-03
Completion:
2026-12-31
Conditions
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Esophageal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
  • RADIATION
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page